This phase 2 RCT (OPAL cohort C) compared neoadjuvant niraparib vs. platinum-taxane doublet chemotherapy in adults with newly diagnosed HRd stage III/IV ovarian cancer (n=36), with pre-IDS overall response rate (ORR) per RECIST v1.1 as the primary endpoint.
Pre-IDS unconfirmed ORR was 31.6% with niraparib vs. 70.6% with platinum-taxane (difference: −39.0%, 80% CI −56.8% to −17.7%), favoring chemotherapy; the trial was closed early for futility. Grade ≥3 adverse events occurred in 42% (niraparib) vs. 59% (platinum-taxane); no fatal serious adverse events in either arm.
- Very small sample size (n=36) after early termination limits statistical power and generalizability. - All responses were partial (no complete responses in either arm), and ORR was unconfirmed/investigator-assessed, introducing potential measurement bias. - 80% CI (not 95%) was used for the primary endpoint comparison, which is unconventional and reduces inferential strength.
Neoadjuvant niraparib should not replace platinum-taxane chemotherapy in HRd advanced ovarian cancer—response rates were markedly lower and the trial was stopped early for futility. Standard neoadjuvant platinum-based chemotherapy remains the treatment of choice in this setting.
Explore related topics